{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:26Z","timestamp":1788393626107,"version":"build-2803163510"},"reference-count":26,"publisher":"Oceanside Publications Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:p>Current gene therapy for inborn errors of immunity have involved the use of gene addition approaches with viral delivery. This main strategy has had demonstrated success mainly in severe combined immune deficiency, Wiskott-Aldrich syndrome, and chronic granulomatous disease. Despite the increasing success of gene therapy, there are limitations of gene therapy, and, therefore, hematopoietic stem cell transplantation continues to be the preferred option. With improvements in viral delivery through next-generation lentiviral vectors and the advent of gene editing with CRISPR-Cas9, the efficacy and safety of gene therapy may soon surpass hematopoietic stem cell transplantation. Furthermore, these advances improve the viability of gene therapy for inborn errors of immunity primarily through decreased risk of transplantation-related complications. Therefore, despite current limitations, gene therapy for inborn errors of immunity is poised to continue to expand to more patients and indications.<\/jats:p>","DOI":"10.2500\/aap.2024.45.240054","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:31:59Z","timestamp":1726720319000},"page":"384-388","source":"Crossref","is-referenced-by-count":10,"title":["Immunodeficiency: Gene therapy for primary immune deficiency"],"prefix":"10.2500","volume":"45","author":[{"given":"Sarah Y.","family":"Afzal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"McGhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2500\/aap.2024.45.240069","article-title":"Hematopoietic stem cell transplantation for primary immunodeficiency","volume":"45","author":"Alsaati","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41577-022-00800-6","article-title":"Gene therapy for inborn errors of immunity: past, present and future","volume":"23","author":"Fischer","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of lentiglobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2500\/aap.2024.45.240051","article-title":"Diagnostic tests for primary immunodeficiency disorders (PID): Classic and genetic testing","volume":"45","author":"Klangkalya","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jaci.2007.08.048","article-title":"Long-term results of bone marrow transplantation in complete DiGeorge syndrome","volume":"120","author":"Land","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.jaci.2021.10.030","article-title":"TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency (DADA2)","volume":"149","author":"Deuitch","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.jtct.2023.12.148","article-title":"Outcomes following matched sibling donor transplant for severe combined immunodeficiency: a report from the Pidtc","volume":"30","author":"Rayes","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B9","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2019-123432","article-title":"Lentiviral gene therapy with autologous hematopoietic stem and progenitor cells (HSPCs) for the treatment of severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID): results in an expanded cohort","volume":"134","author":"Kohn","year":"2019","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.6093246","article-title":"Prospects for human gene therapy","volume":"226","author":"Anderson","year":"1984","journal-title":"Science"},{"key":"B11","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood.V97.9.2896","article-title":"T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation","volume":"97","author":"Ariga","year":"2001","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JBM.S232650","article-title":"Hematopoietic stem cell therapy for Wiskott-Aldrich syndrome: improved outcome and quality of life","volume":"12","author":"Mallhi","year":"2021","journal-title":"J Blood Med"},{"key":"B13","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood.2019002939","article-title":"Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report","volume":"135","author":"Burroughs","year":"2020","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41591-021-01641-x","article-title":"Long-term safety and efficacy of lentiviral hematopoietic stem\/progenitor cell gene therapy for Wiskott-Aldrich syndrome","volume":"28","author":"Magnani","year":"2022","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2013long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1111777","DOI":"10.3389\/fimmu.2023.1111777","article-title":"Advances in CRISPR\/Cas gene therapy for inborn errors of immunity","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"B20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.hoc.2022.05.001","article-title":"Evolution of gene therapy, historical perspective","volume":"36","author":"Malech","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"B22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.stem.2021.01.001","article-title":"Hematopoietic-stem-cell-targeted gene-addition and gene-editing strategies for \u03b2-hemoglobinopathies","volume":"28","author":"Drysdale","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1015926","DOI":"10.3389\/fphar.2022.1015926","article-title":"Gene therapy for cystic fibrosis: challenges and prospects","volume":"13","author":"Sui","year":"2022","journal-title":"Front Pharmacol"},{"key":"B25","first-page":"365","article-title":"The cost of biotech innovation: exploring research and development costs of cell and gene therapies","volume":"37","author":"Sabatini","year":"2023","journal-title":"Pharmaceut Med"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1715536","DOI":"10.1080\/20016689.2020.1715536","article-title":"Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries","volume":"8","author":"J\u00f8rgensen","year":"2020","journal-title":"J Mark Access Health Policy"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2024\/00000045\/00000005\/art00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:00:41Z","timestamp":1732788041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2024.45.240054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9,1]]}},"alternative-id":["1088-5412(20240901)45:5L.384;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2024.45.240054","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}